Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial academic.oup.com/eurjpc/artic...

Relation of lipoprotein(a) levels with risk of serious bleeding in the ODYSSEY OUTCOMES trial

Elevated levels of lipoprotein(a) [Lp(a)] are associated with an increased risk of atherothrombotic cardiovascular events. Yet, uncertainty persists regard

academic.oup.com

New from @rci.bsky.social: What to do if you witness a cardiac arrest. 🫀 Contributors, including CVC Faculty Drs. Roopinder Sandhu & Sean van Diepen, explain how to spot the signs, start basic CPR, and why quick action could save lives.

Radio Canada International@rci.bsky.social · 2w ago

ici.radio-canada.ca/rci/en/news/...

Among adults with CKD stage 4/5 or on dialysis, low-dose rivaroxaban did not lower cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. ja.ma/3TgP0Tp

Current PAH treatments improve outcomes, but remission remains a critical gap. Experts call for novel biomarkers, refined trial designs, & targeting reverse remodeling to optimize patient care. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

From @jama.com: Among adults with advanced chronic #kidney #disease (#CKD) stage 4 or 5 or on #dialysis, low-dose rivaroxaban did not lower #cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group. ja.ma/4uOPe1P

A recent retrospective cohort study explored the frequency of elevated biomarkers & new clinical cardiac diagnoses in patients hospitalized with influenza or Covid-19. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

In a randomized trial, #Email recruitment increased research participant engagement more than patient portal messaging; message content (altruistic vs individualistic) had no significant overall effect. ja.ma/3Rp5eJ6

In acute #HeartFailure, a risk-stratified emergency department and postdischarge care strategy was equally effective in both females and males for reducing cardiovascular hospitalization or death. ja.ma/49BflAE

The spring issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here ➡️: tinyurl.com/65fbuvfa

❤️ Looking for resources in honour of Heart Failure Awareness Week? Don’t miss our curated collection of articles! ⬇️ ccs.ca/wp-content/u... #CardioSky #CJC #CJCO #CJCPC

In this highlighted review, Dr. Sean van Diepen & co-authors examine epidemiological data to propose a framework for the classification & management of mixed cardiogenic shock. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...

New peer‑reviewed research led by the Precision Health Alliance, coordinated by DCRI, outlines the ethical and regulatory considerations for responsibly advancing gene-editing therapies in precision medicine. dcri.org/news/new-pub... #ClinicalResearch #PrecisionMedicine #GeneEditing #Bioethics

The STRIVE trial found low-dose alteplase does not reduce microvascular obstruction in high-risk STEMI patients. With no clinical advantage & potential safety risks, routine use is not recommended. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

Currently accepting applications for the CVC Scholar Program! 🔬 This program is a unique training opportunity to enhance your research expertise & career in cardiovascular medicine. Learn more & apply here: thecvc.ca/programs-and... #CardioSky

Among Medicare beneficiaries, acute myocardial infarction incidence declined during and after the COVID-19 pandemic; mortality increased during the pandemic and then improved, especially in urban populations. ja.ma/48eNu8I

Management of brain–heart multimorbidity guideline: This clinical practice guideline expands on current cardiovascular guidelines to include evidence from the neurologic and mental health literature. ➡️ www.cmaj.ca/lookup/doi/10.1503/cmaj.251137

Alberta data shows maternal asthma increases risks of preterm birth, low birth weight, & C-sections—with highest risks tied to active asthma & specific inflammatory phenotypes. Learn about this research & more in our 2025 Annual Report ➡️: thecvc.ca/annual-repor...

New meta-analysis data suggests rethinking transfusion strategies for patients with heart attack & anemia. Restrictive strategies were linked to higher cardiac mortality & lower 6-month survival. Learn about this research & more in our 2025 Annual Report: thecvc.ca/annual-repor...

Pooled data from the VICTOR & VICTORIA trials demonstrates vericiguat reduces CV death & HF hospitalizations across the HFrEF spectrum—from stable to recently worsened cases. Learn about this research & other highlights in the 2025 CVC Annual Report: thecvc.ca/annual-repor...

We spoke with Justin Ezekowitz, MD, to discuss his recent analysis of the SODIUM-HF trial, which indicated that dietary salt limitations may only benefit patients at the lowest risk for heart failure, contrary to popular belief. Watch now:

Sodium Restrictions May Only Benefit Patients at Low Risk of HF, With Justin Ezekowitz, MD | HCPLive

Ezekowitz discusses his recent secondary analysis of the SODIUM-HF trial, highlighting the MAGGIC analysis data that implied a very limited benefit.

hcplive.com

We’re pleased to share our 2025 Annual Report: The Arteries of Innovation. Innovation thrives on the circulation of diverse ideas. Discover how the CVC translates high-quality data into clinical solutions bridging the gap from discovery to care. Read the report here➡️: thecvc.ca/annual-repor...

Among older patients with #AtrialFibrillation, abelacimab reduced major or clinically relevant bleeding vs rivaroxaban, with a greater absolute risk reduction in those aged ≥75 years. bit.ly/4alEy1P

Registration is open for the next webinar in our ASCVD Education Series, taking place Thursday, January 29, 2026, at 8:00 p.m. ET. Join us as experts explore evidence‑based strategies to enhance patient outcomes and support best practices in ASCVD management. Register today🔗https://bit.ly/3ZynKiT

In this @jamacardiology.com .com viewpoint, Drs. Armstrong, Bainey, & Granger advocate for aligning #STEMI time metrics with current first-point-of-contact capabilities to ensure optimized outcomes for all patients, regardless of geographic location. jamanetwork.com/journals/jam...

Coronary Reperfusion in Patients With ST-Elevation MI Requiring Transfer

This Viewpoint evaluates the evolution of ST-elevation myocardial infarction guidelines on reperfusion choices and the evidence that adherence to timely reperfusion recommendations affects outcomes in...

jamanetwork.com

The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population. Explore more insights from the VICTOR trial ➡️ https://bit.ly/4blPC0O #HeartFailure

Vericiguat in Heart Failure: Insights From the VICTOR Trial - American College of Cardiology

bit.ly

The winter issue of the Canadian Cardiac Chronicle Newsletter is now available! Read more about our current trials, research highlights, & other recent news & updates here: mailchi.mp/bed47c9edc60...

Now accepting applications! The CVC Scholar Program is a unique training opportunity for early-stage investigators focused on cardiovascular disease research. Learn more & apply ➡️: thecvc.ca/programs-and... #cardiosky #cardiology

In the PISCES trial involving participants receiving hemodialysis, fish oil (n−3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: nej.md/49zWuqo @asnkidney.bsky.social | #KidneyWk

Congratulations to CVC Co-Director Dr. Padma Kaul, who has been named Tier 1 Canada Research Chair in Women and Children’s Cardio-Metabolic Health. 👏 www.ualberta.ca/en/the-quad/...

Meet the U of A's Fall 2025 Canada Research Chairs

ualberta.ca

In STEMI patients with multivessel disease, reduced LVEF increases ischaemic risk — but the COMPLETE trial showed complete revascularisation reduces major CV events regardless of LVEF. #cardiosky #medsky #LVEF #cardiology eurointervention.pcronline.com/article/impa...